These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
775 related articles for article (PubMed ID: 6221496)
1. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment. Soufir JC; Jouannet P; Marson J; Soumah A Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Guerin JF; Rollet J Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439 [TBL] [Abstract][Full Text] [Related]
3. The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme. Bain J; Rachlis V; Robert E; Khait Z Contraception; 1980 Apr; 21(4):365-79. PubMed ID: 6771093 [TBL] [Abstract][Full Text] [Related]
4. Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men. Pangkahila W Int J Androl; 1991 Aug; 14(4):248-56. PubMed ID: 1831798 [TBL] [Abstract][Full Text] [Related]
5. Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception. Knuth UA; Yeung CH; Nieschlag E Fertil Steril; 1989 Jun; 51(6):1011-8. PubMed ID: 2524404 [TBL] [Abstract][Full Text] [Related]
6. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869 [TBL] [Abstract][Full Text] [Related]
7. Use of low-dosage oral cyproterone acetate as a male contraceptive. Wang C; Yeung KK Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091 [TBL] [Abstract][Full Text] [Related]
8. Spermatogenesis in men treated with injections of medroxyprogesterone acetate combined with testosterone enanthate. Frick J; Danner C; Kunit G; Joos H; Köhle R Int J Androl; 1982 Jun; 5(3):246-52. PubMed ID: 7118265 [TBL] [Abstract][Full Text] [Related]
9. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men. Moltz L; Römmler A; Post K; Schwartz U; Hammerstein J Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095 [TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men. Foegh M; Nicol K; Petersen IB; Schou G Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869 [TBL] [Abstract][Full Text] [Related]
11. Radioimmunoassays of ethinyl-norgestrienone (R-2323) and medroxyprogesterone acetate (MPA) and their clinical applicability. Frick J; Bartsch G; Jakse G Urol Res; 1977; 5(2):55-9. PubMed ID: 69351 [TBL] [Abstract][Full Text] [Related]
12. Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters. Barfield A; Melo J; Coutinho E; Alvarez-Sanchez F; Faundes A; Brache V; Leon P; Frick J; Bartsch G; Weiske WH; Brenner P; Mishell D; Bernstein G; Ortiz A Contraception; 1979 Aug; 20(2):121-7. PubMed ID: 487815 [TBL] [Abstract][Full Text] [Related]
13. Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive. Brenner PF; Mishell DR; Bernstein GS; Ortiz A Contraception; 1977 Jun; 15(6):679-91. PubMed ID: 891194 [TBL] [Abstract][Full Text] [Related]
14. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations. Wallace EM; Gow SM; Wu FC J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955 [TBL] [Abstract][Full Text] [Related]
15. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. Matsumoto AM J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626 [TBL] [Abstract][Full Text] [Related]
16. The influence of pharmaceutical compounds on male fertility. Neumann F; Diallo FA; Hasan SH; Schenck B; Traore I Andrologia; 1976; 8(3):203-35. PubMed ID: 793446 [TBL] [Abstract][Full Text] [Related]
17. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate. de Greef WJ; Dullaart J; Zeilmaker GH J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105 [TBL] [Abstract][Full Text] [Related]
18. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding. Lemay A; Faure N; Labrie F; Fazekas AT Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551 [TBL] [Abstract][Full Text] [Related]
20. Administration of norethandrolone and testosterone as a contraceptive agent for men. Brenner PF; Bernstein GS; Roy S; Jecht EW; Mishell DR Contraception; 1975 Feb; 11(2):193-207. PubMed ID: 1112088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]